CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jiangsu Aidea Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jiangsu Aidea Pharmaceutical Co Ltd
No. 69
Xinganquan West Road, Hanjiang District
Phone: +86 51482090238p:+86 51482090238 YANGZHOU, JNG  225008  China Ticker: 688488688488
Business Summary
Jiangsu Aidea Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of human-source protein products. The Company is also engaged in the development and sales of some generic drugs, human immunodeficiency virus (HIV) diagnostic equipment and reagents. The Company is also engaged in the research and development of innovative drugs in anti-Acquired Immune Deficiency Syndrome (AIDS), anti-inflammatory and anti-tumor drugs fields. The Company's human-source protein products mainly include crude ulinastatin, crude urekline, crude urokinase and intermediates of ulinastatin. The Company mainly distributes its products within domestic market.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances
2833 Medicinal chemicals and botanical products
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board HeliangFu 61 8/21/2023 1/1/2014
President, Chief Executive Officer, Chief Operating Officer JieZhang 52 8/21/2023 3/14/2023
Chief Financial Officer ChuanhongZhu 51 9/15/2023 9/15/2023
11 additional Officers and Directors records available in full report.

General Information
Number of Employees: 476 (As of 12/31/2023)
Outstanding Shares: 420,782,808 (As of 12/31/2023)
Shareholders: 10,144
Stock Exchange: SHA
Fax Number: +86 51487736366


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024